Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000017

Drug Information
NameXL844
CompanyExelixis
IndicationAdvanced solid tumours or lymphoma
[ICD9: 140-199, 202.8   ICD10: C00-C75, C7A, C7B, C81-C96]
Suspended in Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C14H17N5O2/c15-6-3-9-21-12-5-2-1-4-11(12)18-14(20)19-13-10-16-
7-8-17-13/h1-2,4-5,7-8,10H,3,6,9,15H2,(H2,17,18,19,20)
InChIKeyUVSSZSQSZGKMAL-UHFFFAOYSA-N
Canonical SMILESC1=CC=C(C(=C1)NC(=O)NC2=NC=CN=C2)OCCCN    
Therapeutic ClassAntineoplastic Agents
PubChem Compound IDCID 10016910.
ClinicalTrials.govNCT00475917;
TargetSerine/threonine-protein kinase Chk1Inhibitor[1]
Serine/threonine-protein kinase Chk1Multitarget[1]
Serine/threonine-protein kinase Chk2Inhibitor[1]
Serine/threonine-protein kinase Chk2Multitarget[1]
Ref 1Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle. 2007 Jan 1;6(1):104-10. Epub 2007 Jan 7. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543